A lifelong champion for cancer patients and research—and a cancer survivor himself—Dr. Allen Chao is deeply committed to advancing precision medicine.

Dr. Chao founded Watson Pharmaceuticals, Inc. (NYSE: WPI) and served as Chairman & CEO from 1985 to 2007, then as Chairman through 2008. He led Watson’s growth through internal R&D, licensing, and mergers and acquisitions of pharmaceutical products and technologies. Watson completed its IPO in 1993 (NASDAQ), moved to the NYSE in 1997, joined the S&P 500, and, by Dr. Chao’s retirement in 2008, had approximately $2.8B in annual revenue and $680M+ in EBITDA. Watson later became Allergan plc, which was acquired by AbbVie Inc. in 2020. He brings deep experience in business development, strategic execution, investment, and operational management across the pharmaceutical industry.

The Chao family helped establish the Chao Family Comprehensive Cancer Center (1994) and the H.H. Chao Comprehensive Digestive Disease Center (1999) at the University of California, Irvine Medical Center; a second Chao Family Comprehensive Cancer Center opened in Irvine in 2024.

Dr. Chao earned his Ph.D. in Industrial and Physical Pharmacy from Purdue University in 1973, and received a Doctor of Science degree from Purdue in 2000 recognizing his leadership in the development, manufacturing, and commercialization of medicines.

As CEO of Zephyr AI, Dr. Chao channels his passion and experience into building the partnerships, infrastructure, and teams to apply advanced AI/ML and world-class real-world data assets across the therapeutic lifecycle—helping partners accelerate discovery, validation, and clinical translation so the right therapies can reach patients sooner.